SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

After a significant dip attributed to broader AI sector concerns and potential overreactions to $ORCL news, $CRWV is seeing active debate about its oversold condition and potential for a rebound. The community is closely watching for a recovery, fueled by its strong backlog and Nvidia's involvement, while also considering factors like insider selling and convertible debt. Discussions range from potential short squeezes to long-term bullish perspectives on AI infrastructure.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the company tests driverless cars in Austin, leading to speculation about full autonomy and future robotaxi services. The community is actively discussing the implications of this technology and potential impact on Tesla's valuation, with some pointing to high P/E ratios. Bullish sentiment is fueled by the possibility of new highs and a 'Santa Claus rally,' while bears express concerns about overvaluation and market manipulation.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as traders assess its recent price drop amid concerns about AI infrastructure spending and potential rate hikes. Community discussions range from short-term bearish sentiment and technical analysis to long-term bullish outlooks based on the company's fundamentals and contracted revenue. Investors are weighing the impact of potential AI bubble concerns against IREN's growth prospects and existing deals.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

RKLB is trending due to a mix of factors including a recently aborted launch, planned share sales by Peter Beck, and broader tech sector volatility, leading to community discussion about short-term turbulence versus long-term potential. Despite these headwinds, many investors express confidence in the company's fundamentals and future growth, particularly related to the Neutron rocket and potential government contracts. The stock's movement is also influenced by speculation around a potential SpaceX IPO and its impact on the space sector.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals ($CRML) is trending amid discussions about rare earth element (REE) needs for military applications and reactions to recent drilling results from the Tanbreez Rare Earth Project. Community members are weighing the significance of these results and pondering the potential for future growth. Some are speculating on the impact of potential government investment and partnerships, while others express skepticism about the company's progress and the overall market's valuation of REE assets.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to its explosive move and after-hours continuation, with community members actively discussing potential price targets and the possibility of a short squeeze. The stock, a robotics de-SPAC, is garnering attention despite sector challenges, with some drawing parallels to previous high-flying stocks and anticipating further gains. Traders are closely monitoring key resistance levels and potential breakout points.

$WORKIE is the official workers memecoin on Base.

Workie

Workie crypto is trending with increased community interest, indicated by repetitive mentions of the ticker. Speculation is building around potential catalysts for the token. The community appears to be coalescing around a bullish outlook.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to significant intraday volatility following positive Phase 2b trial data, leading to discussions about potential short squeezes and the company's financial stability. Community chatter revolves around high trading volume, potential price targets, and whether the stock is overvalued or poised for further gains based on its therapeutic pipeline. The stock's webinar presentation is also a key point of discussion, with investors looking for further catalysts.

Mask Network is the core product of Dimension, which is positioned to become the bridge that connects internet users from Web 2.0 to Web 3.0. The foundational technology of Mask Network is a peer-to-peer encrypted messaging application, with new functions continuously being created around this foundation. We at Mask Network are strong believers in the ownership economy. People should own what they produce, people should own their data, their attention and the virtual space they choose to contribute to.  Mask Network integrates decentralized social messaging, borderless payment network, and decentralized file storage and sharing to provide a safe and convenient portal for users to jump right into the continent of decentralized finance and then the new world of Web 3.0.

Mask Network

MASK is trending as community members discuss its potential as an AI stock, drawing comparisons to previous runners. Positive news and a low float are contributing to the bullish sentiment, with some anticipating a continued uptrend. Chatter revolves around potential price targets, but is mostly very speculative.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending as investors anticipate topline results from its Phase 2b study of Rezpegaldesleukin for alopecia areata, expected soon. The community is highly focused on the upcoming data, with some speculating on the potential impact on the stock price based on different outcomes. Discussions also include potential settlement outcomes from their lawsuit with Eli Lilly, adding another layer of speculation to the stock's movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal

Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook. 

<ul class="summary-bullets"><li>As part of the agreement, the U.K. government will lift the threshold used by the NHS to determine if a drug is cost-effective by 25%.</li><li>It has also agreed to a reduction in the industry sales rebate on NHS drug prices to 15% in 2026 from the nearly 23% currently.</li></ul>The United States and the United Kingdom have reached an in-principle agreement on a zero-tariff deal on pharmaceuticals.According to the agreement’s details announced by the Office of the United States Trade Representative, the deal will result in zero tariffs on pharmaceutical products imported in the U.S. from the U.K. It will also lead to an increase in the U.K. government’s spending on the National Health Service (NHS).The agreement between the U.S. and U.K. on pharmaceutical pricing will remain in effect until the end of President Donald Trump’s term in 2029.In exchange, the U.K. government has agreed to a reduction in the industry sales rebate on NHS drug prices to 15% in 2026 from the nearly 23% currently, and remain at that level or below until 2029.<a href="https://stocktwits.com/symbol/AZN">AstraZeneca Plc.’s</a> (AZN) shares were flat in Monday’s opening trade. Retail sentiment around the company trended in the ‘bullish’ territory at the time of writing. AstraZeneca is the U.K.’s largest pharmaceutical company.<h2 class="st-heading-2">Increase In NHS Spending</h2>As part of the agreement, the U.K. government will also lift the threshold used by the NHS to determine if a drug is cost-effective by 25%.“Today’s agreement is a major win for American workers and our innovation economy. We are strengthening supply chains, creating high-quality jobs, and reinforcing America as the world’s premier hub for life-sciences investment,” said Secretary Howard Lutnick.<h2 class="st-heading-2">US-UK Trade Deal</h2>President Trump&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-unveils-us-uk-trade-deal-with-boost-for-steel-agriculture-boeing/chifoL4RbkK">unveiled</a> the U.S.-U.K. trade deal in July, stating that it will open up billions of dollars in market access for exports from the United States. This also included a $10 billion aircraft sale involving Boeing Co. (BA).“With this deal, the U.K. joins the U.S. in affirming that reciprocity and fairness is an essential and vital principle of international trade,” President Trump said following the announcement in July.The deal eased restrictions on exports of beef, ethanol, chemicals, machinery, and other industrial products.&nbsp;<a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is up 41% year-to-date and 37% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-tesla-ridiculously-over-valued-elon-musk/cLI7OPvREie">Michael Burry Takes Aim At Musk’s Tesla Again, Says TSLA Stock Is Still ‘Ridiculously Overvalued’: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

UK Prime Minister Sir Keir Starmer meets with U.S. President Donald Trump, during a bilateral meeting in the Oval Office at the White House

US, UK Reach In-Principle Agreement On Zero-Tariffs On Pharmaceuticals

The agreement between the U.S. and U.K. on pharmaceutical pricing will remain in effect until the end of President Donald Trump’s term in 2029.

Equity

Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in 

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.


Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?

With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?


Pharma ETF (IHE) Hit a 52-Week High

IHE just hit a 52-week high. The ETF is up nearly 30% from its low, powered by $LLY's 9.6% past week surge and bold expansion plans. More upside ahead? 

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio

Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.

A White House official reportedly said on Friday that countries with existing trade agreements with the U.S. would be exempt from the recently announced pharmaceutical tariffs.&nbsp;According to a Reuters report&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/news/reuters.com,2025:newsml_S0N3U402V:0-latest-drug-tariffs-don-t-apply-to-nations-with-trade-deals-white-house-says/">cited</a> by TradingView, when asked whether pharmaceutical tariffs would apply to trading partners such as the European Union and Japan, which already have trade deals, the official stated that the Trump administration would honor the 15% cap as part of those pacts. Other nations with U.S. trade deals include Vietnam, the U.K., Indonesia, and the Philippines. Major partners like India, Canada, and Mexico have yet to finalize&nbsp;an agreement.The clarification comes after President Donald Trump on Thursday announced a 100% tariff on imported, branded, and patented pharmaceutical drugs starting October 1. In his Truth Social&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/115267512131958759">post</a> announcing the tariffs, Trump only highlighted that an exception would be made for any company that is “IS BUILDING their Pharmaceutical Manufacturing Plant in America.” He explained that “is building” refers to “‘breaking ground’ and/or ‘under construction’.”In a note to investors on Friday morning, Jefferies analyst Akash Tewari described the new pharmaceutical tariffs as "a win for Pharma" and "a light at the end of the Trump tunnel," noting that several large-cap companies have already announced U.S. manufacturing projects. Tewari suggested the tariffs and the MFN pilot program may serve as a symbolic “on paper” win ahead of midterms, with limited material impact on pharmaceutical companies.The 100% tariff is higher than what Trump had indicated in August.&nbsp; He&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">stated</a> that tariffs would be increased over time, allowing companies sufficient time to build factories and relocate production. Trump had said he would start by charging a “small tariff” on pharmaceuticals and raise the rate over a year or more to 150% and even 250%.The&nbsp;<a href="https://stocktwits.com/symbol/IHE">iShares U.S. Pharmaceuticals ETF (IHE)</a> edged 1.3% higher in midday trade. On Stocktwits, retail sentiment around the ETF improved to ‘neutral’ from ‘bearish over the past day. Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rose 0.86% with retail sentiment trending in ‘bullish’ territory as chatter rose to ‘high’ from ‘normal’ levels.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pce-report-core-inflation-holds-steady-at-2-9-in-august/chDViYeR3eE">PCE Report: Core Inflation Holds Steady At 2.9% In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report

According to a Reuters report cited by TradingView, a White House official stated that the Trump administration will honor the 15% pharmaceutical tariff cap for trade partners such as the EU and Japan, as outlined in existing agreements.

Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

IHE
iShares U.S. Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IHE News

IHEiShares U.S. Pharmaceuticals ETF